Thromboxane Generation in Patients with Essential Hypertension or Cerebrovascular Disease and Effect of Oral Aspirin

M Matsumoto; T Nukada; O Uyama; S Yoneda; M Imaizumi; T Miyamoto; N Kayama

doi:10.1055/s-0038-1650072

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1980; 44(01): 016-022
DOI: 10.1055/s-0038-1650072

Original Article

Schattauer GmbH Stuttgart

Thromboxane Generation in Patients with Essential Hypertension or Cerebrovascular Disease and Effect of Oral Aspirin

M Matsumoto

^*The First Department of Internal Medicine, Osaka University Medical School, Osaka, Japan

,

T Nukada

^*The First Department of Internal Medicine, Osaka University Medical School, Osaka, Japan

,

O Uyama

^*The First Department of Internal Medicine, Osaka University Medical School, Osaka, Japan

,

S Yoneda

^*The First Department of Internal Medicine, Osaka University Medical School, Osaka, Japan

,

M Imaizumi

^*The First Department of Internal Medicine, Osaka University Medical School, Osaka, Japan

,

T Miyamoto

^**The Central Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan

,

N Kayama

^**The Central Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan

› Author Affiliations

Abstract

PDF Download

Summary

The ability of platelets to synthesize thromboxane B₂ (TxB₂) from arachidonic acid (AA) or prostaglandin H₂ (PGH₂) was studied in 26 control subjects, 40 patients with essential hypertension, 20 patients with cerebrovascular disease (CVD) not taking aspirin and 11 patients with CVD taking aspirin. The activity of platelets to form TxB₂ from AA or PGH₂ was measured using 1 — ¹⁴C arachidonic acid or 1—¹⁴C PGH₂ as a substrate. There was no significant difference in TxB₂ generation from AA or PGH₂ among the platelets collected from the control subjects, hypertensive patients and CVD patients not taking aspirin.

In CVD patients taking aspirin, marked suppression was observed in TxB₂ synthesis from AA, but no suppression in TxB₂ synthesis from PGH₂. At least 750 mg aspirin per day were required for nearly complete suppression of TxB₂ generation from AA.

Key words

Thromboxane generation - Hypertension - Cerebrovascular disease - Aspirin - Prostaglandin - Platelet

PDF (1265 kb)

References

References
1 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Nat Acad Sci USA 1975; 72: 2994-2998
2 Blackwell GJ, Duncombe WG, Flower RJ, Parsons MF, Vane JR. The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Pharmacol 1977; 59: 353-366
3 Bunting S, Moncada S, Vane JR. The effects of prostaglandin endoperoxides and thromboxane A₂ on strips of rabbit coeliac artery and certain other smooth muscle preparations. Br J Pharmacol 1976; 57: 462p-463p
4 Moncada S, Gryglewski RJ, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelets aggregation. Nature 1976; 263: 663-665
5 Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 1976; 12: 685-713
6 Moncada S, Gryglewski RJ, Bunting S, Vane JR. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 1976; 12: 715-737
7 Gryglewski RJ, Dembińska-Kièć A, Zmuda A, Gryglewska T. Prostacyclin and thromboxane A₂ biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978; 31: 385-394
8 Szczeklik A, Gryglewski RJ, Musiał J, Grodzińska L, Serwońska M, Marcinkiewicz E. Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb. Haemostas 1978; 40: 66-74
9 Sinzinger H, Feigl W, Silberbauer K. Prostacyclin generation in atherosclerotic arteries. Lancet 1979; 2: 469
10 Sinzinger H, Clopath P, Silberbauer K, Auerswald W. Prostacyclin synthesis in human and experimental atherosclerosis. Atherosclerosis 1979; 34: 345-347
11 Dembińska-Kièć A, Rücker W, Schönhöfer PS. Prostacyclin-dependent differences in TXA₂ formation by platelets from normal and atherosclerotic rabbits. Atherosclerosis 1979; 33: 217-226
12 Amezcua JL, O'Grady J, Salmon JA, Moncada S. Prolonged paradoxical effect of aspirin on platelet behaviour and bleeding time in man. Thromb Res 1979; 16: 69-79
13 Pace-Asciak CR, Carrara MC, Rangaraj G, Nicolaou KC. Enhanced formation of PGI₂, a potent hypotensive substance, by aortic rings and homogenates of the spontaneously hypertensive rat. Prostaglandins, 1978; 15: 1005-1012
14 Okuma M, Yamori Y, Ohta K, Uchino H. Production of prostacyclin-like substance in stroke-prone and stroke-resistant spontaneously hypertensive rats. Prostaglandins, 1979; 17: 1-7
15 Yoshimoto T, Yamamoto S, Hayaishi O. Selective inhibition of prostaglandin endoperoxide thromboxane isomerase by 1-carboxyalkylimidazoles. Prostaglandins 1978; 16: 529-540
16 Miyamoto T, Yamamoto S, Hayaishi O. Prostaglandin synthetase system – Resolution into oxygenase and isomerase components. Pro Nat Acad Sci USA 1974; 71: 3645-3648
17 Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 1973; 19: 1350-1356
18 Eggstein M, Kreutz FH. Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. I. Mitteilung. Prinzip, Durchführung und Besprechung der Methode. Klin Wochenschr 1966; 44: 262-267
19 Danta G. Platelet adhesiveness in cerebrovascular disease. Atherosclerosis 1970; 11: 223-233
20 Andersen LA, Gormsen J. Platelet aggregation and fibrinolytic activity in transient cerebral ischemia. Acta Neurol Scand 1976; 55: 76-82
21 Couch JR, Hassanein RS. Platelet aggregation, stroke, and transient ischemic attack in middle-aged and elderly patients. Neurology 1976; 26: 888-895
22 Kobayashi I, Fujita T, Yamazaki H. Platelet aggregability measured by screen filtration pressure method in cerebrovascular diseases. Stroke 1976; 7: 406-409
23 Dougherty Jr JH, Levy DE, Weksler BB. Platelet activation in acute cerebral ischemia. Lancet 1977; 1: 821-824
24 Mehta J, Mehta P, Burger C, Pepine CJ. Platelet aggregation studies in coronary artery disease. Part 4. Effect of aspirin. Atherosclerosis 1978; 31: 169-175
25 Matsumoto M, Nukada T, Uyama O, Yoneda S, Imaizumi M, Miyamoto T, Kayama N. Arachidonic acid induced platelet aggregation in patients with essential hypertension and cerebrovascular disease. (in preparation)
26 Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformation of arachidonic acid in human platelets. Proc Nat Acad Sci USA 1974; 71: 3400-3404
27 Nugteren DH. Arachidonate lipoxygenase in blood platelets. Biochim Biophys Acta 1975; 380: 299-307
28 O'Brien JR, Oxon DM, Path FC. Effects of salicylates on human platelets. Lancet 1968; 1: 779-783
29 Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61: 379-385
30 Woodbury DM, Fingl E. Analgesic-antipyretics, anti-inflammatory agents, and drugs employed in the therapy of gout. In: Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics . Macmillan Publishing Co., New York: 1975. p. 325-358
31 Rance MJ, Jordan GJ, Nichols JD. A simultaneous determination of acetylsalicylic acid, salicylic acid and salicylamide in plasma by gas liquid chromatography. J Pharm and Pharmacol 1975; 27: 425-429
32 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-319
33 Szczeklik A, Gryglewski RJ, Grodzińska L, Musiał J, Serwońska M, Marcinkiewicz E. Platelet aggregability, thromboxane A₂ and malonaldehyde formation following administration of aspirin to man. Thromb Res 1979; 15: 405-413
34 Dyken ML. Assessment of the role of antiplatelet aggregating agents in transient ischemic attacks, stroke and death. Stroke 1979; 10: 602-604